Jefferies Group LLC restated their buy rating on shares of Eli Lilly and Company (NYSE:LLY) in a research note published on Monday, September 11th, MarketBeat reports. The firm currently has a $89.00 target price on the stock.
A number of other equities analysts also recently commented on LLY. Goldman Sachs Group, Inc. (The) reiterated a buy rating and set a $92.00 price objective on shares of Eli Lilly and in a research report on Tuesday, May 16th. Sanford C. Bernstein restated an outperform rating and issued a $88.00 target price on shares of Eli Lilly and in a research report on Sunday, May 21st. TheStreet downgraded Eli Lilly and from a b+ rating to a c rating in a research report on Wednesday, May 31st. BidaskClub upgraded Eli Lilly and from a sell rating to a hold rating in a research report on Wednesday, June 14th. Finally, Zacks Investment Research downgraded Eli Lilly and from a hold rating to a sell rating in a report on Tuesday, June 27th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $88.27.
Eli Lilly and (NYSE LLY) opened at 83.33 on Monday. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $86.72. The firm has a market cap of $87.91 billion, a P/E ratio of 36.06 and a beta of 0.34. The firm’s 50-day moving average is $80.84 and its 200 day moving average is $82.02.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company earned $0.86 earnings per share. Equities analysts forecast that Eli Lilly and will post $4.16 earnings per share for the current year.
In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 590,000 shares of company stock worth $48,551,300 in the last 90 days. Insiders own 0.20% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Pathstone Family Office LLC raised its position in shares of Eli Lilly and by 100.0% in the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after buying an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. purchased a new position in shares of Eli Lilly and in the 2nd quarter worth $494,000. Acrospire Investment Management LLC raised its position in shares of Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the period. MPS Loria Financial Planners LLC purchased a new position in shares of Eli Lilly and in the 2nd quarter worth $128,000. Finally, San Francisco Sentry Investment Group CA purchased a new position in shares of Eli Lilly and in the 2nd quarter worth $129,000. 75.72% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with our FREE daily email newsletter.